Evidence map›Paper›PMID 34196954›Full record

ArticleNeurotoxicity research2021

Brain Targeting and Toxicological Assessment of the Extracellular Vesicle-Packaged Antioxidant Catalase-SKL Following Intranasal Administration in Mice.

Sarah H Hayes, Qingfan Liu, Sureka Selvakumaran, Matthew J Haney, Elena V Batrakova, Brian L Allman, Paul A Walton, Patti Kiser, Shawn N Whitehead

Abstract read
PubMed Publisher
In one paragraph

Article in Neurotoxicity research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Targeting respiratory virus-induced reactive oxygen species in airways diseases.European respiratory review : an official journal of the European Respiratory Society · 2025
    Review
  7. Extracellular vesicles for developing targeted hearing loss therapy.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Sarah H Hayes *Department of Anatomy and Cell Biology, The University of Western Ontario, London, ON, Canada. sarah.hayes@schulich.uwo.ca.
Qingfan Liu *Department of Anatomy and Cell Biology, The University of Western Ontario, London, ON, Canada.
Sureka SelvakumaranDepartment of Anatomy and Cell Biology, The University of Western Ontario, London, ON, Canada.
Matthew J HaneyEshelman School of Pharmacy, University of North Carolina At Chapel Hill, Chapel Hill, NC, USA.
Elena V BatrakovaEshelman School of Pharmacy, University of North Carolina At Chapel Hill, Chapel Hill, NC, USA.
Brian L AllmanDepartment of Anatomy and Cell Biology, The University of Western Ontario, London, ON, Canada.
Paul A WaltonDepartment of Anatomy and Cell Biology, The University of Western Ontario, London, ON, Canada.
Patti Kiser *Department of Pathology and Laboratory Medicine, The University of Western Ontario, London, ON, Canada.
Shawn N Whitehead *Department of Anatomy and Cell Biology, The University of Western Ontario, London, ON, Canada.
Western University · CAUniversity of North Carolina at Chapel Hill · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The antioxidant enzyme catalase represents an important therapeutic target due to its role in mitigating cellular reactive oxygen species that contribute to the pathogenesis of many disease states. Catalase-SKL (CAT-SKL), a genetically engineered, peroxisome-targeted, catalase derivative, was developed in order to increase the therapeutic potential of the enzyme, and has previously been shown to be effective in combating oxidative stress in a variety of in vitro and in vivo models, thereby mitigating cellular degeneration and death. In the present study we addressed important considerations for the development of an extracellular vesicle-packaged version of CAT-SKL (evCAT-SKL) as a therapeutic for neurodegenerative diseases by investigating its delivery potential to the brain when administered intranasally, and safety by assessing off-target toxicity in a mouse model. Mice received weekly intranasal administrations of evCAT-SKL or empty extracellular vesicles for 4 weeks. Fluorescent labeling for CAT-SKL was observed throughout all sections of the brain in evCAT-SKL-treated mice, but not in empty extracellular vesicle-treated mice. Furthermore, we found no evidence of gross or histological abnormalities following evCAT-SKL or empty extracellular vesicle treatment in a full-body toxicological analysis. Combined, the successful brain targeting and the lack of off-target toxicity demonstrates that intranasal delivery of extracellular vesicle-packaged CAT-SKL holds promise as a therapeutic for addressing neurological disorders.

Indexed as

Administration, IntranasalAnimalsAntioxidantsBrainCatalaseExtracellular VesiclesFemaleMaleMiceMice, Inbred C57BLRAW 264.7 CellsAntioxidantsCatalasecatalase-SKL, ratBrain targetingCatalaseExtracellular vesicleIntranasal deliveryToxicity

Identifiers

PMID34196954
OpenAlexW3175106066

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.